3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
77.7
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/25 A Issuer sale

Director

85,011 0.1134%
7/1/25 A Issuer sale

Chief Financial Officer

738,955 0.9861%
7/1/25 A Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--% - - 3.54B
+6.63%+5.13%+68.86%+145.20% 1,148B
+1.53%+2.84%+47.48%+89.01% 652B
+1.68%+1.96%+29.16%+109.31% 505B
+0.73%+2.45%+54.26%+68.96% 384B
+3.83%-0.62%+69.01%+42.32% 348B
+2.38%+2.65%+34.31%+57.95% 294B
+2.26%+0.55%+3.92%+28.92% 264B
+1.97%+3.01%+57.91%+76.14% 244B
+4.03%+5.36%+39.76%+116.14% 197B
Average +2.11%+2.42%+44.96%+81.55% 448.57B
Weighted average by Cap. +2.25%+2.89%+50.22%+95.97%
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - SpringWorks Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SWTX Stock